Editor-in-Chief: Godefridus J. Peters
Journal Rank: Impact Factor 2024: 5.2 - Q1 (ONCOLOGY); CiteScore 2024: 8.3 - Q1 [Pharmacology(medical)]
Median time to first editorial decision: 9 days

Cancer Drug Resistance

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Articles Collection
Exploring the Future of Cancer Immunotherapy, the Impact of Treg Cell Discovery, and Ethical Considerations in CRISPR Research
Prestigious Honor, Global Impact: 58 CDR Editorial Board Members Ranked Among World's Top 2% Scientists, Reinforcing the Journal's Leadership in the Field
Advancing the Fight Against Cancer Drug Resistance Together: Share Your Findings and Enjoy Anniversary Savings!
Marking a 13% rise, CDR continues to lead the field of cancer drug resistance.
This marks a notable 25.8% increase from last year's score of 6.6, underscoring the CDR's rising academic impact and global recognition.

Submission Deadline: 31 Aug 2026

Published articles: 0

Integrating Multi-Omics and Artificial Intelligence in Deciphering Cancer Drug Resistance

Submission Deadline: 31 Jul 2026

Published articles: 0

Coming soon.

Articles Collection
Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/